Clinical trials: Leucogen
Leukemia, Acute Lymphoblastic, Acute Lymphoid Leukemia
Erwinase Master Treatment Protocol
The purpose of this study is to make Erwinase available to patients with acute lymphoblastic leukemia (ALL) who have had previous allergic reactions to certain formulations of L-asparaginase.
- Trial name
- EMTP (NCT00590915)
- Testing
- Erwinia L-asparaginase
- Sponsor
- Phoenix Children's Hospital
Leukemia, Precursor-B Acute Lymphoblastic Leukemia
Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
The goal of this clinical research study is to learn if a chemotherapy combination called augmented Berlin-Frankfurt-Munster (BFM), when also combined with ofatumumab or rituximab, can help to control precursor-B ALL or LL in…
- Conditions
- Leukemia, Precursor-B Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Lymphoma
- Trial name
- NCT02419469
- Testing
- Cytarabine, Daunorubicin, Vincristine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Drug-Induced Diabetes Mellitus
Glucose Intolerance and Diabetes Related to Treatment With Steroids and PEG- Asparaginase in Children and Adolescents With ALL and Lymphoma
The overall survival of acute lymphoblastic leukemia (ALL) and lymphoma in children and adolescents is above 90%. The survival rate has increased significantly during the last decades as a consequence of more intensive…
- Conditions
- Precursor Cell Lymphoblastic Leukemia-Lymphoma, Drug-Induced Diabetes Mellitus, Impaired Glucose Tolerance, Lymphoma
- Trial name
- NCT05873322
- Where
- Denmark
- Volunteers
- 100 people
- Sponsor
- Aarhus University Hospital
Relapsed Acute Lymphoblastic Leukemia, Allergy to PEG e.Coli Asparaginase
Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)
This is a phase I study using the Erwinia form of asparaginase in place of the E. coli form using a standard re-induction regimen (Vincristine, Dexamethasone, Doxorubicin) for patients with relapsed ALL who have developed an…
- Conditions
- Relapsed Acute Lymphoblastic Leukemia, Allergy to PEG e.Coli Asparaginase, Allergy to Native e.Coli Asparaginase
- Trial name
- NCT00928200
- Testing
- Erwinase, Vincristine, Dexamethasone
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
Leukemia
Pharmacokinetics of Asparaginase and Antibody Formation in Interfant-06
Asparaginase is an important drug in the treatment of childhood leukemia including in infant (<1 year). The prognosis for infants is bad.
- Trial name
- NCT01025804
- Where
- 6 sites in Denmark, Finland and 3 more
- Volunteers
- 15 people
- Sponsor
- Aarhus University Hospital
Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia
Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (Closed to Accrual 4-22-2011)
This pilot clinical trial studies the side effects of pegaspargase when given together with combination chemotherapy in treating patients with newly diagnosed high-risk acute lymphoblastic leukemia.
- Conditions
- Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia
- Trial name
- NCT00866307
- Testing
- Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride
- Where
- 28 sites in United States, Australia and 1 more
- Volunteers
- 104 people
- Sponsor
- Children's Oncology Group
Acute Lymphoblastic Leukemia
Hemostasis During Asparaginase Treatment in Acute Lymphoblastic Leukemia(ALL)
Asparaginase is an important drug in the treatment of childhood leukemia. One of the rare but severe side effects to the treatment is thrombosis in or outside the central nervous system.
- Trial name
- NCT01094392
- Where
- 4 sites in Denmark
- Volunteers
- 65 people
- Sponsor
- Aarhus University Hospital
Acute Lymphoblastic Leukemia
Correlation of Polymorphisms of Lipoprotein Lipase (LpL) and Apolipoprotein E (Apo E) With Lipid Profile of Children With Acute Lymphoblastic Eukaemia During Therapy With L - Asparaginase.
Haematological malignancies constitute the most common neoplastic disease in child population, with acute leukemia occupying the number one spot with a percentage of 32.8%.
- Trial name
- NCT04364451
- Testing
- Correlation of Polymorphisms of Lipoprotein Lipase (LpL) and Apolipoprotein E (Apo E) With Lipid Profile of Children With Acute Lymphoblastic Leukaemia During Therapy With L - Asparaginase
- Where
- Greece
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Aristotle University Of Thessaloniki
Drug Toxicity
Real World Asparaginase Therapy Toxicity
This research study is being done to learn more about the short term and long term side effects of treatment with asparaginase drugs, which are commonly used in acute lymphoblastic leukemia (ALL) or acute lymphoblastic lymphoma…
- Trial name
- NCT07008027
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- St. Jude Children's Research Hospital
Leukemia, Lymphocytic, Acute
NOPHO ALL-2008 Pilot Study on Consolidation Therapy for Children and Adolescents With Acute Lymphoblastic Leukemia
The present pharmacokinetic (PK)-pharmacodynamic (PD) study will explore the toxicity and antileukemic response during the initial 3 months of individualised therapy of children and young adults with acute lymphoblastic leukemia…
- Trial name
- NCT00548431
- Testing
- 6-mercaptopurine
- Where
- 3 sites in Denmark, Sweden
- Volunteers
- 38 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Nasopharyngeal Carcinoma (NPC)
Compassionate Use of Asparaginase and Pembrolizumab Combination Theaapy for Nasopharyngeal Carcinoma
The goal of this study is to investigate the outcomes of patients with locoregionally advanced nasopharyngeal carcinoma (LA-NPC) or recurrent-metastatic nasopharyngeal carcinoma (RM-NPC) treated with a combination of immune…
- Trial name
- NCT06676293
- Testing
- Anti-PD1, asparaginase
- Where
- Taiwan
- Volunteers
- 8 people
- Sponsor
- Chang Gung Memorial Hospital
Relapse Leukemia
Outcome Following Truncation of Asparaginase
This study aimed to investigate the outcome of patients who had their asparaginase treatment truncated in the NOPHO ALL2008 protocol.
- Trial name
- NCT03987542
- Where
- Denmark
- Volunteers
- 1,401 people
- Sponsor
- Birgitte Klug Albertsen
Acute Lymphoid Leukemia
Efficacy and Safety of Recombinant Asparaginase in Infants With Previously Untreated Acute Lymphoid Leukemia (ALL)
This non-controlled multicentre phase II study is designed to assess the safety and to describe (in relation to children of higher age) the pharmacodynamics of recombinant ASNase (rASNase) for first-line treatment of infants (< 1…
- Trial name
- NCT00983138
- Testing
- recombinant asparaginase
- Where
- 17 sites in Germany, Netherlands
- Volunteers
- 12 people
- Sponsor
- medac GmbH
Acute Lymphoblastic Leukemia
Expanded Access Program: Safety of Erythrocytes Encapsulating L-asparaginase (GRASPA®) in Combination With Polychemotherapy in Patients Under 55 Years Old With Acute Lymphoblastic Leukemia (ALL) at Risk to Receive Other Formulation of Asparaginase
Early Access Program to provide L-asparaginase encapsulated in Erythrocyte (GRASPA®) for patient unable to receive any other form of Asparaginase.
- Trial name
- EAP (NCT02197650)
- Testing
- suspension of erythrocytes encapsulating L-asparaginase
- Where
- 10 sites in France
- Sponsor
- ERYtech Pharma
Extranodal NK/T-cell Lymphoma, Nasal Type
MESA Versus ESA in the Treatment of Early Stage NK/T-cell Lymphoma
Extranodal natural killer (NK)/T-cell lymphoma (ENKTL), nasal type, is a distinct and heterogeneous histopathologic subtype of non-Hodgkin lymphoma (NHL), accounting for 5%~10%.
- Trial name
- NCT02631239
- Testing
- Methotrexate, Etoposide, Dexamethasone
- Where
- China
- Volunteers
- 256 people
- Sponsor
- Ruijin Hospital
Acute T Cell Leukemia
Ruxolitinib Plus LVP in Patients With R/R ETP-ALL
To determine the maximum tolerated dose (MTD), if present, and dose schedule of ruxolitinib in combination with L-ASP, vincristine, and prednisone (LVP) in patients with relapsed-and-refractory (R/R) early T precursor acute…
- Trial name
- NCT03613428
- Testing
- Ruxolitinib, Vincristine, Prednisone
- Volunteers
- 12 people
- Sponsor
- Sichuan University
Acute Lymphoblastic Leukemia, in Relapse
GRASPA (Erythrocytes Encapsulating L-asparaginase) in Patients With Relapse of Acute Lymphoblastic Leukemia
Asparaginase is a cornerstone in the treatment of ALL, but its utility is limited by toxicities including hypersensitivity. Clinical allergy is associated with inactivation of asparaginase by antibodies (A-Abs), which can also…
- Trial name
- GRASPIVOTALL (NCT01518517)
- Testing
- GRASPA, L-asparaginase
- Where
- 28 sites in Belgium, France
- Volunteers
- 85 people
- Sponsor
- ERYtech Pharma
Acute Lymphoblastic Leukemia
The Association Between Asparaginase Enzyme Activity Levels and Toxicities in Childhood Acute Lymphoblastic Leukaemia in NOPHOALL 2008
Evaluation of the association between risk and severity of asparaginase associated toxicities and asparaginase enzyme activity levels in children with Acute Lymphoblastic Leukemia treated in the NOPHO-ALL 2008 protocol.
- Trial name
- NCT04187248
- Testing
- Asparaginase
- Where
- Denmark
- Volunteers
- 1,248 people
- Sponsor
- Aarhus University Hospital
Childhood Acute Lymphoblastic Leukemia, Childhood Lymphoblastic Lymphoma
Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration
This study evaluates the median duration of therapeutic serum asparaginase activity (SAA) levels after administration of calaspargase pegol (Cal-PEG) and the potential association between peak SAA levels and duration of…
- Trial name
- NCT07221656
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
Acute Lymphoblastic Leukemia
Pharmacokinetics and Immunogenicity of the First Doses of PEG-Asparaginase -An ALLTogether Pilot Study
Acute lymphoblastic leukemia (ALL) is the most common malignant disease in childhood. Survival rates exceed 90% in children and 75% in adults (aged 18-45 years).
- Trial name
- NCT04843150
- Where
- 2 sites in Denmark
- Volunteers
- 320 people, healthy volunteers welcome
- Sponsor
- Aarhus University Hospital